Destiny Pharma PLC Director/PDMR Shareholding (8614A)

TIDMDEST

RNS Number : 8614A

Destiny Pharma PLC

26 May 2023

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director/PDMR Shareholding

Brighton, United Kingdom - 26 May 2023 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it was notified on 26 May 2023 that on that same day, Nick Rodgers, Chairman of the Company, purchased 20,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 30.19 pence.

Following the purchase, Mr. Rodgers' beneficial interest in the Company is 238,901 Ordinary Shares, representing 0.25 per cent. of the total issued share capital.

For further information, please contact:

Destiny Pharma plc

Dr Debra Barker, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

Optimum Strategic Communications

Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

[phone]

[e-mail]

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the Company, please visit https://www.destinypharma.com

Further information is disclosed below pursuant to Article 19(3) of the Market Abuse Regulation.

 
            1.   Details of the person discharging managerial responsibilities 
                  / person closely associated 
 a)              Name                             Nick Rodgers 
                -------------------------------  ----------------------------------- 
            2.   Reason for the Notification 
                -------------------------------------------------------------------- 
 a)              Position/status                  Chairman 
                -------------------------------  ----------------------------------- 
 b)              Initial notification/Amendment   Initial Notification 
                -------------------------------  ----------------------------------- 
 3.              Details of the issuer, emission allowance market participant, 
                  auction platform, auctioneer or auction monitor 
                -------------------------------------------------------------------- 
 a)              Name                             Destiny Pharma plc 
                -------------------------------  ----------------------------------- 
 b)              LEI                              213800O9WH9Z38EHAC95 
                -------------------------------  ----------------------------------- 
 4.              Details of the transaction(s): section to be repeated 
                  for (i) each type of instrument; (ii) each type of transaction; 
                  (iii) each date; and (iv) each place where transactions 
                  have been conducted 
                -------------------------------------------------------------------- 
 a)              Description of the               Ordinary shares of 1 pence each in 
                  Financial instrument,            Destiny Pharma Plc 
                  type of instrument 
                -------------------------------  ----------------------------------- 
                 Identification code              GB00BDHSP575 
                -------------------------------  ----------------------------------- 
 b)              Nature of the transaction        Purchase of Ordinary Shares 
                -------------------------------  ----------------------------------- 
 c)              Price(s) and volume(s)            Price(s)         Volume(s) 
                                                    30.1898 pence    20,000 
                                                                    ---------- 
                -------------------------------  ----------------------------------- 
 d)              Aggregated information: 
                   *    Aggregated volume           See 4c) above 
 
 
                   *    Price 
                -------------------------------  ----------------------------------- 
 e)              Date of the transaction          26 May 2023 
                -------------------------------  ----------------------------------- 
 f)              Place of the transaction         London Stock Exchange, AIM Market 
                                                   (XLON) 
                -------------------------------  ----------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFFSERIRFIV

(END) Dow Jones Newswires

May 26, 2023 10:27 ET (14:27 GMT)